Adenovirus Infections in Heart Transplantation

Florescu, Diana F.; Kwon, Joong Y.; Dumitru, Ioana

doi:10.1097/crd.0b013e31828da5b7

Cited by 19 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of AdV infections among SOT recipients is 5 to 22%, usually within the first 6 months posttransplantation. 2,4,38,156,196,197 AdV infections have been noted in liver, 198,199 renal, 140,142,146,[200][201][202] heart, 196,203,204 intestinal, 205,206 and lung [207][208][209] transplant recipients. Among SOT recipients, risk factors for AdV include: pediatric age 4,38,198 ; donor-positive/recipient-negative AdV status 38 ; receipt of antilymphocyte antibodies.…”

Section: Solid Organ Transplant Recipientsmentioning

confidence: 99%

Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention

Lynch

Kajon

2016

Semin Respir Crit Care Med

430

178

View full text Add to dashboard Cite

Adenoviruses (AdVs) are DNA viruses that typically cause mild infections involving the upper or lower respiratory tract, gastrointestinal tract, or conjunctiva. Rare manifestations of AdV infections include hemorrhagic cystitis, hepatitis, hemorrhagic colitis, pancreatitis, nephritis, or meningoencephalitis. AdV infections are more common in young children, due to lack of humoral immunity. Epidemics of AdV infection may occur in healthy children or adults in closed or crowded settings (particularly military recruits). The disease is more severe and dissemination is more likely in patients with impaired immunity (e.g., organ transplant recipients, human immunodeficiency virus infection). Fatality rates for untreated severe AdV pneumonia or disseminated disease may exceed 50%. More than 50 serotypes of AdV have been identified. Different serotypes display different tissue tropisms that correlate with clinical manifestations of infection. The predominant serotypes circulating at a given time differ among countries or regions, and change over time. Transmission of novel strains between countries or across continents and replacement of dominant viruses by new strains may occur. Treatment of AdV infections is controversial, as prospective, randomized therapeutic trials have not been conducted. Cidofovir is the drug of choice for severe AdV infections, but not all patients require treatment. Live oral vaccines are highly efficacious in reducing the risk of respiratory AdV infection and are in routine use in the military in the United States, but currently are not available to civilians.

show abstract

Section: Solid Organ Transplant Recipientsmentioning

confidence: 99%

Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention

Lynch

Kajon

2016

Semin Respir Crit Care Med

430

178

View full text Add to dashboard Cite

show abstract

“…Image courtesy of Kyoko Kurosawa) dysfunction [194]. AdV DNA in biopsy specimens is associated with worse outcomes among pediatric heart transplant patients [195,196]. AdV in SOT patients is most common in pediatric transplantation, small bowel recipients, and those who receive lymphocyte depletion [1].…”

Section: Adenovirusmentioning

confidence: 99%

Respiratory Viral Pathogens in Solid Organ and Hematopoietic Stem Cell Transplant Recipients

Pergam

Ison

2020

Emerging Transplant Infections

View full text Add to dashboard Cite

“…Adenovirus has been associated with rejection, ventricular dysfunction, coronary vasculopathy, and the need for retransplantation. The current standard treatment for adenovirus is cidofovir, but outcomes are not optimal [91].…”

Section: Viralmentioning

confidence: 99%